Journal Title:
The Oncologist
Original Publication Date:
Apr 2023
Bone Marrow Disease(s):
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
Journal Title:
The Oncologist
Original Publication Date:
Apr 2023
Bone Marrow Disease(s):
Raising the bar for lower-risk myelodysplastic syndromes
Journal Title:
Leukemia & Lymphoma
Original Publication Date:
Apr 2023
Bone Marrow Disease(s):
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
Journal Title:
Blood
Original Publication Date:
Apr 2023
Bone Marrow Disease(s):
Newly revised 2023 MDS response criteria
Journal Title:
Blood
Original Publication Date:
Apr 2023
Bone Marrow Disease(s):
Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care
Journal Title:
Transplantation and Cellular Therapy
Original Publication Date:
Apr 2023
Bone Marrow Disease(s):
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents
Journal Title:
Current Hematologic Malignancy Reports
Original Publication Date:
Apr 2023
Purpose of review: To discuss novel targeted therapies under investigation for treatment of myelodysplastic neoplasms (MDS).
Bone Marrow Disease(s):
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases
Journal Title:
Internal and Emergency Medicine
Original Publication Date:
Apr 2023
VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently described pathological entity. It is an acquired monogenic autoinflammatory disease caused by somatic mutations of the UBA1 gene in blood cells precursors; the gene encodes one of the two E1 enzyme isoforms that initiates ubiquitylation in cell's cytoplasm. VEXAS syndrome leads to systemic inflammation, with all organs and tissues potentially involved.
Bone Marrow Disease(s):
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study
Journal Title:
American Journal of Hematology
Original Publication Date:
Apr 2023
Bone Marrow Disease(s):
Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia
Journal Title:
Blood
Original Publication Date:
Apr 2023
Bone Marrow Disease(s):